Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder
Dysfunction of glutamatergic neurotransmission may be relevant to the pathogenesis of post-traumatic stress disorder (PTSD). Preclinical and clinical evidence suggests that PTSD symptoms could be alleviated following enhancement of neurotransmission mediated at the N-methyl-D-aspartate (NMDA) subtype of glutamate receptors. Eleven patients with chronic PTSD participated in a double-blind, placebo-controlled, cross-over trial with 50 mg/d D-cycloserine which acts as a partial agonist at the glycine regulatory site on the NMDA receptor. D-cycloserine treatment resulted in significant improvements in numbing, avoidance, and anxiety symptoms; however, similar effects were also observed during placebo treatment. In addition, D-cycloserine treatment resulted in a significant (p=0.03), reduction in the perseverative error scores as measured by the Wisconsin Card Sorting Test. This pilot study is the first to assess the efficacy of a NMDA receptor modulator for PTSD treatment and its results warrant further, larger-scale investigation.(Received October 8 2001)
(Reviewed January 27 2002)
(Revised July 8 2002)
(Accepted July 10 2002)
Key Words: D-cycloserine; N-methyl-D-aspartate receptor; post-traumatic stress disorder.
c1 Address for correspondence: Dr U. Heresco-Levy, Psychiatry Division, Ezrath Nashim-Herzog Memorial Hospital, PO Box 35300, Jerusalem 91351, Israel. Tel.: +972-2-5316-906 Fax: +972-2-6536-075 E-mail: email@example.com